Skip to main content

Advertisement

SpringerLink
Log in

Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Desmedt C, Fornili M, Clatot F et al (2020) Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index. J Clin Oncol. https://doi.org/10.1200/JCO.19.01771

    Article  PubMed  Google Scholar 

  2. Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804. https://doi.org/10.1001/jamaoncol.2018.0137

    Article  PubMed  PubMed Central  Google Scholar 

  3. Shachar SS, Deal AM, Weinberg M et al (2017) Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res 23:3537–3543. https://doi.org/10.1158/1078-0432.CCR-16-2266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was not funded.

Author information

Authors and Affiliations

  1. Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) IRCCS, via Piero Maroncelli 40, 47014, Meldola, Italy

    Michela Palleschi, Emanuela Scarpi & Chiara Casadei

Authors
  1. Michela Palleschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emanuela Scarpi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Casadei
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MP, ES, CC: conceived the study and wrote the letter.

Corresponding author

Correspondence to Chiara Casadei.

Ethics declarations

Conflict of interest

Michela Palleschi, Emanuela Scarpi and Chiara Casadei declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Research involving human and animal rights

This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Palleschi, M., Scarpi, E. & Casadei, C. Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?. Breast Cancer Res Treat 185, 255–256 (2021). https://doi.org/10.1007/s10549-020-05923-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-020-05923-9

Search

Navigation